

# Syngene

Ref: Syn/CS/SE/Reg 30/Feb/2021-22/08

Syngene International Limited

Biocon SEZ, Biocon Park, Plot No. 2 &  
3, Bommasandra Industrial Area, IV  
Phase, Jigani Link Road, Bengaluru  
560 099, Karnataka, India

T +91 80 6775 8000

F +91 80 6775 8808

CIN: L85110KA1993PLC01493

[www.syngeneintl.com](http://www.syngeneintl.com)

March 01, 2022

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
<b>Scrip Code: 539268</b>	<b>Scrip Symbol: SYNGENE</b>

Dear Sir/Madam,

**Sub: Change in Directorate**

**Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015**

Pursuant to the provisions of regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to notify that Dr Carl Decicco, Director (DIN: 08576667) has informed the Company that he has not been able to appear for the Online Proficiency Test conducted by the Indian Institute of Corporate Affairs before the due date of February 27, 2022 and has accordingly ceased to be an Independent Director of the Company with effect from February 28, 2022. It is further informed that the Board of Directors has approved the appointment of Dr Carl Decicco as Additional Director (Non-executive Non-independent) of the Company with effect from March 01, 2022 till three months from the date of his appointment or the next general meeting of the Company, whichever is earlier.

Kindly note that the Company will continue to fulfil the requirement of Board constitution as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 even after the change in the directorship status of Dr Decicco from Independent Director to Non-Executive Non-Independent Director.

Brief profile of Dr Carl Decicco is attached with this intimation.

We request you to kindly take this information on record.

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

**Priyadarshini Mahapatra**  
**Company Secretary & Compliance Officer**

Encl: as above

## Dr Carl Decicco- Brief Profile



Dr Carl Decicco completed post-doctoral studies with Professor EJ Corey at Harvard University. He was a teaching fellow at the University of British Columbia and obtained his Ph.D. with Professor Gordon Lange in Organic Chemistry from the Guelph-Waterloo Center in Ontario, Canada. He has 22 years of experience in the pharmaceutical industry. Dr. Decicco retired as the Chief Scientific Officer at Foghorn Therapeutics in Cambridge MA in January 2022. Prior to joining Foghorn in 2018, he served as the Head of Discovery at Bristol Myers Squibb (BMS). He is a Partner at Flagship Pioneering and serves on the Board of Cellarity Pharmaceuticals.

Dr Decicco is not related to any of the directors of the Company. He has not been debarred from holding the office of director by virtue of any SEBI order or any other such authority.